Phablecare closed this acquisition for an undisclosed sum, betting on the start-up's holistic approach to Type 1 Diabetes management
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
